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Chymotrypsin-like elastases (CELAs) are pancreatic serine
proteinases that digest dietary proteins. CELAs are typically
expressed in multiple isoforms that can vary among different
species. The human pancreas does not express CELA1 but
secretes two CELA3 isoforms, CELA3A and CELA3B. The rea-
sons for the CELA3 duplication and the substrate preferences of
the duplicated isoforms are unclear. Here, we tested whether
CELA3A and CELA3B evolved unique substrate specificities to
compensate for the loss of CELA1. We constructed a phage
library displaying variants of the substrate-like Schistocerca gre-
garia proteinase inhibitor 2 (SGPI-2) to select reversible high
affinity inhibitors of human CELA3A, CELA3B, and porcine
CELA1. Based on the reactive loop sequences of the phage dis-
play-selected inhibitors, we recombinantly expressed and puri-
fied 12 SGPI-2 variants and determined their binding affinities.
We found that the primary specificity of CELA3A,CELA3B, and
CELA1 was similar; all preferred aliphatic side chains at the so-
calledP1position, the aminoacid residue locateddirectlyN-ter-
minal to the scissile peptide bond. P1 Met was an interesting
exception that was preferred by CELA1 but weakly recognized
by the CELA3 isoforms. The extended substrate specificity of
CELA3A and CELA3B was comparable, whereas CELA1 exhib-
ited unique interactions at several subsites. These observations
indicated that the CELA1 and CELA3 paralogs have some dif-
ferent but also overlapping specificities and that the duplicated
CELA3AandCELA3B isoformsdid not evolve distinct substrate
preferences. Thus, increased gene dosage rather than specificity
divergence of the CELA3 isoforms may compensate for the loss
of CELA1 digestive activity in the human pancreas.
Digestive serine proteinases are secreted by the pancreas and
include trypsins, chymotrypsins, and elastases, which cleave
dietary protein substrates with unique substrate specificities
primarily determined by the P1 amino acid forming the scissile
peptide bond (Schechter and Berger nomenclature of interac-
tions between proteinases and their substrates (1)). Pancreatic
elastases were recently renamed chymotrypsin-like elastases to
avoid confusion with the homologous neutrophil elastase.
Digestive enzymes are typically expressed in multiple isoforms,
and the number and properties of these isoenzymes can vary
significantly among the different vertebrate species making
clear assignment of orthology challenging at best. The advent of
the genomic era facilitated the comprehensive identification
and annotation of digestive enzyme isoforms; however, func-
tional studies have been slow to keep up with the omics revolu-
tion, and the physiological significance of digestive proteinase
diversity has remained relatively poorly understood even in
humans.
Elastases were first defined by their ability to solubilize insol-
uble elastin by Hungarian scientists Baló and Banga in 1949 (2),
who demonstrated the presence of such elastolytic activity in
pancreatic homogenates of the pig (3). Subsequent purification
of porcine elastase 1 (CELA1) allowed unambiguous assign-
ment of the elastolytic activity to this serine proteinase (4–6).
CELA1was shown to adsorb to the surface of elastin because of
its basic character and then to cleave elastin atmultiple Ala-Ala
and Ala-Gly peptide bonds (7–9). The P1 Ala specificity was
confirmed using various peptide and protein substrates; fur-
thermore, cleavages after P1Val, Leu, Ile, Gly, and Ser were also
documented indicating that CELA1 prefers P1 amino acids
with smaller aliphatic side chains (5, 6, 8–15). Finally, X-ray
crystallography demonstrated that the specificity pocket of
porcine CELA1 was restricted at the mouth by Val-216 (chy-
motrypsin numbering) and partially occluded at the bottom by
Thr-226, which explained the characteristic P1 preference and
the exclusion of aromatic side chains (16). Curiously, the
ortholog of porcine CELA1 is not expressed in the human pan-
creas due to evolutionary mutations in the 5 promoter and
enhancer regions (17, 18).
A second proteinase with elastolytic activity, named elastase
2 (CELA2), was isolated from the pig (8, 19–21) and human
pancreas (23, 24) andwas subsequently cloned from the human
(25–27), rat (28), and bovine pancreas (29). Surprisingly, when
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tested on elastin (8, 9), oxidized insulin (30), or p-nitroanilide
peptide substrates (31, 32), CELA2 exhibited chymotrypsin-
like primary substrate specificity and cleaved these substrates
after Leu, Met, Phe, and Tyr rather than Ala or Val residues.
Relative to chymotrypsins, however, the catalytic efficiency was
about 100-fold lower when measured on p-nitroanilide sub-
strates(32).Thechymotrypsin-likesubstratespecificitywascon-
sistent with the presence of Gly-216 and Ser-226 in the speci-
ficity pocket of CELA2.Cloning of the human cDNAresulted in
the identification of two highly similar genes, named CELA2A
andCELA2B, indicating recent gene duplication (27). Although
expressed at the mRNA level, the CELA2B protein has never
been isolated or detected. When expressed recombinantly,
human CELA2B did not function as an active proteinase as a
result of natural evolution-drivenmutations absent in the func-
tional CELA2A enzyme (33).
A third major human pancreatic elastase was isolated by
multiple groups independently and named proteinase E (or
protease E) (34), elastase 1 (23), and cholesterol-binding pro-
tein (36, 37). N-terminal protein sequencing and cDNAcloning
confirmed the identity of these proteinases of acidic character
as elastase 3 (CELA3) and also revealed that the human gene
underwent duplication giving rise to CELA3A and CELA3B
(38–40). Both isoforms are expressed at themRNAandprotein
levels to a comparable extent (39, 40). Human CELA3B was
found to have poor elastolytic activity but readily degraded
casein and hemoglobin and hydrolyzed small ester and amide
substrates with a P1 Ala (34). Further characterization of the
human and porcine enzymes on peptide and protein substrates
indicated cleavages after not only a P1Ala but alsoVal, Leu, Ser,
and Thr residues indicating that the primary substrate specific-
ity is similar to that of porcine CELA1 (23, 37, 41–43). Interest-
ingly, the proenzyme of humanCELA3B, but not that of human
CELA3A, forms binary complexes with procarboxypeptidase
A1 and A2, and a similar binary complex was isolated from the
pig pancreas (see Ref. 44 and references therein). Ruminants
such as cattle, goat, and sheep secrete ternary complexes that
also contain chymotrypsinogen C (CTRC)4 (45). During purifi-
cation of the bovine ternary complex, proproteinase E (CELA3)
becomes autolyzed at the Val-30–Asn-31 peptide bond giving
rise to subunit III, an N-terminally truncated inactive protein-
ase E, the true identity of which has been shrouded in mystery
for decades (Refs. 44, 46, 47 and references therein).
Silencing of the archetypal CELA1 in the human pancreas
and duplication of the CELA3 genes raise the intriguing possi-
bility that these two evolutionary events are linked, and
CELA3AorCELA3Bmight serve as a surrogate forCELA1with
respect to substrate specificity. Therefore, in this study we
characterized the substrate specificity of human CELA3A and
CELA3B and compared it with pig CELA1 using phage display-
selected proteinase inhibitor variants that bind in a substrate-
like manner.
Results
Selection of SGPI-2 Inhibitor Variants against Human
CELA3A and CELA3B and Porcine CELA1 by Phage Display—
To analyze the substrate specificity of CELA3A and CELA3B,
we performed directed evolution of the Schistocerca gregaria
proteinase inhibitor 2 (SGPI-2) that binds in a substrate-like
manner to its cognate proteinases. To compare the character-
istics of the CELA3 substrate-binding sites to those of the
CELA1 paralog, we also evolved variants against porcine
CELA1. The pig enzyme served as a surrogate model for the
evolutionarily silenced human ortholog (17, 18).We previously
successfully selected tight-binding inhibitors from SGPI-2
libraries against several serine proteinases, including bovine
and crayfish trypsins, humanCTRC, andhumanmannan-bind-
ing lectin-associated serine proteinases 1 and 2 (48–50). Fur-
thermore, we demonstrated that wild-type SGPI-2 bound to
CELA3A andCELA3Bwith low butmeasurable affinity (KD2
and0.3 M, respectively) (49). For this study, we constructed
anM13 bacteriophage library displaying SGPI-2 variants on the
p8 coat protein where we fully randomized the P4, P2, P1, P1,
P2, and P4 positions in the reactive loop while keeping the
structurally important P3 and P3 Cys residues intact (Fig. 1).
Selection of tight-binding phage clones from the library con-
taining 3  108 variants was performed against CELA3A and
CELA3B, and in a separate experiment a library of 7.5  108
variants was selected against CELA1. Three rounds of panning
were performed. Clones from the third selection cycle were
tested for target binding by phage ELISA, and binders were
sequenced. The enrichment after the third panning was 3500-
fold on CELA3A, 1100-fold on CELA3B, and 3500-fold on
CELA1.
CELA3A andCELA3B Selected Pools of SGPI-2 Variants with
Similar Binding Loop Sequences—DNA sequencing of selected
phages revealed 34 and 49 unique phage clones against
CELA3A and CELA3B, respectively (Table 1). To visualize the
sequence patterns in the reactive loop of the inhibitors, we gen-
erated codon-normalized sequence logos (Fig. 2). The logos
indicated similar binding loop sequences selected against the
two elastases, with some small but notable differences. Some-
what surprisingly, Ala was not the preferred amino acid at the
P1 position where longer side-chain aliphatic residues (Ile, Leu,
Met, Val) were primarily selected. CELA3A preferred a P1 Ile
over Leu, but Met was excluded, whereas a P1 Leu over Ile was
4 The abbreviations used are: CTRC, chymotrypsin C; Boc, t-butoxycarbonyl;
TEV, tobacco etch virus; Suc, N-succinyl.
FIGURE 1. Primary structure of wild-type SGPI-2. The amino acid positions
within the binding loop that were subjected to randomization in the phage
display library are highlighted in white. Figure taken from Ref. 49. This figure
was originally published in Ref. 49. © the American Society for Biochemistry
and Molecular Biology.
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preferred by CELA3B, and Met was also allowed. The striking
dominance of Thr at the P2 position in all logos does not rep-
resent elastase-specific selection, but rather it is the result of
hydrogen bonding interactions of the Thr side chain with the
core of the protein that are important for stabilizing the canon-
ical conformation of the proteinase binding loop. At the P1
position Met was selected overwhelmingly against both elasta-
ses. Arg also occurred in this positionwith a higher frequency in
the CELA3B logo. Compared with P1, a somewhat weaker
conservation emerged at the P2 position, where CELA3A and
CELA3B showed preference for Leu and Tyr, respectively. Fur-
thermore, a P2 Glu was also selected more frequently against
CELA3A than CELA3B. Finally, at position P4 CELA3A dis-
played preference for His, but no clear amino acid conservation
was apparent at this position for CELA3B. Similarly, only a low
level of selection was observed at position P4 with some prefer-
ence for Tyr and Ala by both elastases.
Porcine CELA1 Selected an SGPI-2 Binding Loop Sequence
Pattern Characteristically Different from Those Obtained for
the Human CELA3 Enzymes—The sequence logo (Fig. 2C) rep-
resenting 59 unique binding clones (Table 1) revealed a nar-
rower specificity of CELA1 at several binding loop positions.
Most notably, in sharp contrast with the more permissive S4
subsite of human CELA3 proteinases, Ala was almost exclu-
sively selected by pig CELA1 at P4. Moreover, the S1 binding
pocket of the CELA1 enzyme strongly preferred a P1 Met,
although this residue was rare or even absent among CELA3
binders. On the primed side of the scissile bond amino acids
Met, Arg, and Leu were selected with similar frequency at the
P1 position, although both CELA3 enzymes preferred Met.
CELA1 showed an overwhelming preference for aromatic side
chains at P2, but the human CELA3 enzymes either preferred
or at least readily tolerated the presence of aliphatic residues at
this position. Finally, the P4 side chain seemed to have the least
impact on the interaction of the inhibitor and the CELA1
enzyme.
Inhibitors Derived from the Phage-selected CELA3 Sequence
LogosWere Produced as Recombinant Proteins—On the basis of
the selected sequence patterns, we produced recombinant
SGPI-2 variants. To generate a meaningful set of inhibitors
while keeping their number manageable, we focused on the
CELA3 selected patterns. We designed 12 variants (Table 2) to
test the roles of the P4, P1, P1, P2, and P4 positions in deter-
mining inhibitory affinity and selectivity. The variants were
named SGPI-2 E1 through E12. Variants E1–E6 had the com-
mon P4–P4 reactive loop sequence, Tyr-Cys-Thr-(Xaa)-Met-
Leu-Cys-His, where the highlightedXaa (P1) residuewas varied
by incorporating Leu, Ile, Val, Met, Ala, and Ser. Although not
selected from our library, Ser was included among the tested P1
residues because cleavage after Ser by CELA3B was reported
previously (43), and we also observed autolytic cleavages in the
CELA3A and CELA3B activation peptides after Ser residues
(44). In variants E7–E12, we tested the effects of a P4Ala (versus
Tyr), a P1Arg (versusMet), a P2Glu andTyr (versus Leu), and
a P4 Ala (versus His). Note that variant E7 contained a P1 Ile,
whereas variants E8–E12 carried a P1 Leu residue. The SGPI-2
variants were expressed in Escherichia coli and purified to
homogeneity. The binding affinities of the inhibitors against
TABLE 1
Amino acid sequence of the reactive loop of SGPI-2 variants selected by phage display against human CELA3A (34 clones), CELA3B (49 clones),
and pig CELA1 (59 clones)
The primary structure of variants unique at the DNA level is shown for positions P4-P3-P2-P1-P1-P2-P3-P4 with P1 residues in bold type.
CELA3A CELA3B CELA1
ACTAMLCH ACTAQLCY SCTLMACW ACTAMYCA ACTMLYCG
ACTLMACH ACTLMACA SCTLMLCH ACTARWCA ACTMLYCG
ACTLMLCA ACTLMLCE WCTLMACD ACTARWCG ACTMLYCQ
ACTLMLCF ACTLMLCG WCTLMLCD ACTIMWCN ACTMLYCS
ACTLMLCH ACTLMLCN YCTAMYCF ACTIRYCQ ACTMMYCA
ACTLMLCH ACTMELCW YCTARACA ACTLIWCG ACTMMYCG
ACTLMLCH ACTMLLCA YCTIKLCH ACTLMACH ACTMMYCW
ACTVMLCH ACTMLPCG YCTIRLCY ACTLMFCH ACTMRFCG
HCTIMACH ACTVMLCV YCTLMACV ACTLMWCG ACTMRLCV
HCTLMLCH ACTVMYCP YCTLMACY ACTLMYCG ACTMRLCY
HCTLMLCY ACSIRYCE YCTLRECF ACTLMYCL ACTMRWCA
HCTLMLCY FCTAMECG YCTLRFCA ACTLRFCP ACTMRWCD
LCTIMLCH FCTARFCH YCTLRYCQ ACTLRWCA ACTMRWCD
LCTIMLCH FCTLMWCW YCTVMLCS ACTLRWCG ACTMRWCD
LCTIMLCH HCTIRLCH YCTVRWCW ACTLLYCG ACTMRWCG
LCTIRLCW HCTLRWCY ACTLLYCG ACTMRWCG
LCTLMACH LCTIMLCH ACTMAYCA ACTMRWCS
LCTLMACH LCTIRHCE ACTMIWCG ACTMRYCD
LCTLMLCY LCTLMACA ACTMIWCG ACTMRYCG
LCTVMLCW LCTLMACY ACTMLFCQ ACTMRYCG
WCTIAECH LCTLMLCA ACTMLFCY ACTMRYCG
WCTLMLCD LCTLMLCH ACTMLLCV ACTMRYCV
WCTVMLCH LCTLMLCM ACTMLPCA ACTMRYCS
WCTVMYCP LCTLMLCS ACTMLPCF GCTMLYCG
YCTAMLCW LCTLMSCH ACTMLPCH YCTLRWCD
YCTIMACH LCTLRHCH ACTMLPCI
YCTIMLCH LCTLRYCP ACTMLPCS
YCTIRECH LCTLRYCW ACTMLWCG
YCTIRLCH LCTMRYCH ACTMLWCG
YCTLMLCH LCTVMLCM ACTMLWCG
YCTVMACH LCTVMLCN ACTMLWCN
YCTVMACY LCTVRACY ACTMLWCV
YCTVMLCH MCTLMLCD ACTMLYCA
YCTVMLCH MCTLMYCS ACTMLYCG
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human CELA3A, CELA3B, and porcine CELA1 were deter-
mined in equilibrium binding assays. Furthermore, to charac-
terize the selectivity of the variants, their affinity toward the
human chymotrypsins CTRC, CTRB1, and CTRB2 was also
measured. Table 2 lists the equilibrium dissociation constants
(KD) in nanomolar units for each inhibitor variant against the
six pancreatic serine proteinases.
Inhibitors Carrying the Isoform-selected Consensus Strongly
Improve CELA3 Binding but Reveal Negligible Isoform
Specificity—The logos indicate only a loose consensus for
CELA3A and CELA3B corresponding to variants E2 and E9,
respectively. The parent molecule SGPI-2 inhibited CELA3A
and CELA3B with moderate affinities (KD values of 1952 nM
and 337 nM, respectively (49)). In contrast, E2 inhibited
FIGURE 2. SGPI-2 variants selectedbyphagedisplay against humanelastases CELA3AandCELA3Bandpig CELA1. Sequence logo representation of the
binding loop of phage display-selected inhibitors against human CELA3A (34 clones), CELA3B (49 clones), and porcine CELA1 (59 clones). The overall height of
the stack of symbols indicates the sequence conservation at that position, and the height of symbols within the stack indicates the relative frequency of each
amino acid. The colors indicate the chemical properties of the amino acid side chains as follows: aliphatic is green; aromatic is orange; acidic is red; basic is dark
blue; and polar with no charge is light blue. Note that the Cys residues shown in gray at the P3 and P3 positions were not randomized. Their symbol height
represents the maximal height corresponding to a completely conserved residue. The logo was generated with the WebLogo program (55).
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CELA3A with KD of 4.5 nM corresponding to a 434-fold
improvement, and E9 inhibited CELA3B with a KD of 10 nM
representing a 34-fold improved binding. Additional small
increases in affinity were achieved by changing the P2 to Glu
(versusTyr) inE2 (variant E7,KD3.6nMagainstCELA3A) and the
P4position toAla (versusTyr) inE9 (variantE10,KD6.1nMagainst
CELA3B). These strongest variants showed 542- and 55-fold
increased binding to CELA3A and CELA3B, respectively, relative
to wild-type SGPI-2. Overall, all tested variants exhibited compa-
rable binding toward the two elastases with no significant isoform
selectivity, indicating that the substrate specificity ofCELA3Aand
CELA3B is highly similar. The most selective CELA3A and
CELA3B binders (variants E7 and E11) showed only a 4.7- and
4.3-fold selectivity, respectively, over the other isoform.
Canonical serine proteinase inhibitors become slowly
cleaved after the P1 residue by their cognate enzymes, and if no
other cleavage occurs, the process leads to equilibrium as the
cleaved inhibitor remains functional. However, the cleaved
inhibitor may be more susceptible to additional degradation
and inactivation by the cognate proteinase. To test for this pos-
sibility, we characterized the stability of the six P1 variants by
measuring KD values after 1 h and overnight (16 h) incubations
with CELA3A and CELA3B. We found that extended incuba-
tion caused either no change or only a small loss in affinity,
which was less than 2-fold in most cases (range 0.9–3.0-fold),
indicating that inhibitor degradation is not a significant con-
founding factor in our experiments (Table 3).
P1 Preference of Elastases and Chymotrypsins—Inhibitors
E1–E6 differed only at their P1 position and allowed evaluation
of the P1 preference of the proteinases studied. We observed a
striking similarity with respect to the P1 specificity of human
CELA3A andCELA3Bwith relativelyminor differences in side-
chain preference. Branched aliphatic side chains (Leu, Ile, and
Val) and Ala conferred the highest affinity (KD range 4.5–27 nM
for CELA3A and 12–35 nM for CELA3B), whereasMet was less
favored (KD 142 and 246 nM, respectively), and Ser was inferior
(KD 1170 and 478 nM, respectively). Porcine CELA1 bound
inhibitors with P1 branched side chains and Ala weaker than
the human elastases (KD range 30–113 nM) but did not discrim-
inate against Met (KD 41 nM), which was the most frequently
selected P1 amino acid by CELA1. A P1 Ser was poorly recog-
nized by porcine CELA1 as well (KD 1492 nM).
TheKD values of purified P1 variants E1–E6 against CELA3A
reflected the amino acid preference order at the same position
of the sequence logo (Table 2 and Fig. 3). Thus, Ile at the P1
position provided the highest affinity toward the enzyme and
was followed by Leu, Val, and Ala with 2.4-, 2.9-, and 6-fold
higher KD values, respectively. No SGPI-2 clones with P1 Met
or Ser were selected in the phage display experiments, and
accordingly, variants withMet(E4) or Ser(E6) at the P1 position
were 32- and 260-fold weaker inhibitors of CELA3A, respec-
tively, relative to the consensus E2 variant with P1 Ile. CELA3B
exhibited a small 1.3-fold preference toward a P1 Leu over Ile,
whereas variants with P1 Val and Ala bound 2.9- and 1.7-fold
weaker, respectively (Table 2 and Fig. 3). As seenwithCELA3A,
inhibitor variants with P1 Met and Ser exhibited a 21- and
40-fold decrease in binding affinity toward CELA3B, respec-
tively. The poor binding of variant E4 with a P1 Met is some-
what surprising considering that Met was more frequently
selected in the logo than Val or Ala. Moreover, the binding
affinity of variant E6 with a P1 Ser was only 2-fold weaker than
that of E4 with P1Met, even though Ser was completely absent
from the P1 position of the sequence logo.
These discrepancies suggest that in terms of binding con-
straints the E4 variant is not an ideal representative of the P1
Met-containing pool of phage display-selected variants. This
can be due to a synergistic contribution of individual binding
looppositionstotheoverallbindingenergy.Suchcontextdepen-
dence of the P1 Met function is supported by the sequences of
the selected clones (Table 1). The CELA3A-selected pool con-
tained no P1 Met variant at all, but we tested the P1 contribu-
tion in the context of the CELA3A-selected consensus, Tyr-
Cys-Thr-Xaa-Met-Leu-Cys-His. If even a single residue of the
CELA3A consensus is incompatible with a P1 Met, it could
readily explain the observed effect. In fact, out of the 49 unique
TABLE 2
Inhibition of pancreatic elastases and chymotrypsins by SGPI-2 variants
The table lists the equilibrium dissociation constant (KD) values in nanomolar units of concentration. Averages of two independent KD determinations are shown. Binding
loop sequences are indicated with P1 residues in bold type. Differences at positions P4, P1, P2, and P4 are underlined and italicized. NDmeans no inhibition was detected.
Variant P4 P3 P2 P1 P1 P2 P3 P4 CELA3A CELA3B CELA1 CTRC CTRB1 CTRB2
E1 Tyr-Cys-Thr-Leu-Met-Leu-Cys-His 11 12 30 0.001 1579 128
E2 Tyr-Cys-Thr-Ile-Met-Leu-Cys-His 4.5 16 38 0.22 ND ND
E3 Tyr-Cys-Thr-Val-Met-Leu-Cys-His 13 35 113 5.9 ND ND
E4 Tyr-Cys-Thr-Met-Met-Leu-Cys-His 142 246 41 0.088 ND 799
E5 Tyr-Cys-Thr-Ala-Met-Leu-Cys-His 27 20 64 1992 ND 78565
E6 Tyr-Cys-Thr-Ser-Met-Leu-Cys-His 1170 478 1492 4240 ND ND
E7 Tyr-Cys-Thr-Ile-Met-Glu-Cys-His 3.6 17 990 1.6 13928 ND
E8 Tyr-Cys-Thr-Leu-Arg-Leu-Cys-His 42 102 89 0.21 7049 2281
E9 Tyr-Cys-Thr-Leu-Met-Tyr-Cys-His 43 10 1.3 0.001 1177 226
E10 Ala-Cys-Thr-Leu-Met-Leu-Cys-His 10 6.1 9.2 0.002 32 0.47
E11 Ala-Cys-Thr-Leu-Met-Tyr-Cys-His 78 18 0.70 0.009 16 1.1
E12 Tyr-Cys-Thr-Leu-Met-Leu-Cys-Ala 40 38 59 0.014 1953 174
TABLE 3
Effect of extended incubation on the inhibition of humanCELA3A and
CELA3B by SGPI-2 variants
The table lists the equilibrium dissociation constant (KD) values in nanomolar units
of concentration determined after 1- and 16-h incubation times. Binding loop
sequences are indicated with P1 residues in bold type. Averages of two independent
KD determinations are shown.
Variant P4 P3 P2 P1 P1 P2 P3 P4 CELA3A CELA3B
1 h 16 h 1 h 16 h
E1 Tyr-Cys-Thr-Leu-Met-Leu-Cys-His 11 15 12 15
E2 Tyr-Cys-Thr-Ile-Met-Leu-Cys-His 4.5 8.8 16 37
E3 Tyr-Cys-Thr-Val-Met-Leu-Cys-His 13 39 35 56
E4 Tyr-Cys-Thr-Met-Met-Leu-Cys-His 142 268 246 222
E5 Tyr-Cys-Thr-Ala-Met-Leu-Cys-His 27 64 20 26
E6 Tyr-Cys-Thr- Ser-Met-Leu-Cys-His 1170 1295 478 808
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CELA3B-selected clones, four have a P1 Met, three accompa-
nied with a P4 Ala and one with a P4 Leu, but none with a P4
Tyr. Moreover, 28 of the 49 CELA3B-selected clones (57%)
have a P1 Met, but none of these combines with a P1 Met.
Taken together, this suggests that a P1Met functions poorly in
the dual context of P4 Tyr and P1Met, although based on the
individual sequences, all other tested P1 residues are compati-
ble with these side chains.
Human CTRC bound inhibitors with a P1 Leu with remark-
able (picomolar) affinity confirming its previously described
primary substrate specificity (49). Binding of SGPI-2 variants
with P1Met, Ile, and Val were 88-, 220-, and 5900-fold weaker,
respectively, whereas variants with P1 Ala and Ser were poor
CTRC inhibitors with micromolar affinity.
Binding of all P1 variants to CTRB1 and CTRB2 was very
weak and in most cases undetectable. Measurable binding with
both enzymes was observed only with variant E1 carrying a P1
Leu. Interestingly, CTRB2bound this variantmore than 10-fold
tighter thanCTRB1, and a similar relationshipwas observed for
all other inhibitor variants (E8–E12) where binding to both
chymotrypsins could be measured (Table 2).
Met at the P1 Position Is Preferred Over Arg by Elastases—
The CELA3A- and CELA3B-selected sequence logos indicated
a strong preference forMet at the P1 position, which was even
more strictly conserved than the P1 position. Nevertheless,
CELA3B appeared to be permissive toward Arg in the phage
selections. The CELA1 enzyme selected Met followed by Arg
and Leu in comparable proportions. In direct binding experi-
ments, however, variant E8 carrying a P1Arg (versus a P1Met
in E1) exhibited 8.5-fold decreased affinity toward CELA3B,
while binding to CELA3A and porcine CELA1 was reduced by
3.8- and 3-fold, respectively (Table 2 and Fig. 4). Note that
sequences of E1 andE8 differ from theCELA1-selected consen-
sus (Ala-Cys-Thr-Met-Arg-Trp-Cys-Gly) at 3–4 positions,
which might explain why the Arg-containing variant was not
preferred by CELA1.
Remarkably, the P1 Arg inhibited binding to CTRC by 210-
fold, and affinity toward CTRB1 and CTRB2 was diminished
4.5- and 18-fold, respectively.
P2 Position Controls Binding to CELA1 but Not to CELA3
Isoforms—The phage-selected sequence patterns suggested
that CELA1 strongly prefers Tyr or Trp at the P2 position,
whereas the two CELA3 isoforms have slightly different
requirements. CELA3A showed a clear preference for Leu,
whereas Tyrwas selected against CELA3Bmore often. Further-
more, CELA3A seemedmore tolerant toward an acidic P2Glu
side chain than CELA3B. To test whether these differences can
be exploited for the design of an isoform-selective elastase
inhibitor, we compared binding of inhibitors with a P1 Ile and
P2 Leu versusGlu (E2 and E7) and inhibitors with a P1 Leu and
P2 Leu versus Tyr (inhibitor pairs E1–E9 and E10-E11). A P2
Glu (versus Leu) caused no significant changes in affinity
toward CELA3A or CELA3B (Table 2 and Fig. 5A) but reduced
binding 26- and 7.3-fold to porcine CELA1 and human CTRC,
respectively. In contrast, a P2Tyr (versus Leu) decreased bind-
ing almost 4-fold to CELA3A but had no impact on inhibitor
affinity toward CELA3B, which is in good accordance with the
corresponding logos of CELA3AandCELA3B. Remarkably, the
P2Tyr (versus Leu) increased binding affinity to pig CELA1 by
13–23-fold in perfect accordance with the CELA1 logo, but it
had no appreciable effect on binding to CTRC, CTRB1, or
CTRB2 (Fig. 5, B and C).
P4 Side Chain Does Not Confer Selectivity among Elastase
Isoforms—The P4 position of the sequence logos exhibits an
interesting difference. Although this is the least conserved posi-
tion for CELA3B and CELA1, a distinct preference for His is
FIGURE3.Effect of theP1aminoacid inSGPI-2on the inhibitionofhuman
CELA3A, CELA3B and porcine CELA1. A, equilibrium dissociation constant
(KD) values determined for six inhibitors (E1–E6, see Table 2) containing the
indicated P1 residues. B, relative KD values normalized to the E1 inhibitorwith
a P1 Leu. Measurements were carried out as described under “Experimental
Procedures.”
FIGURE 4. Effect of the P1 residue (Met versus Arg) on the inhibition of
elastases and chymotrypsins by SGPI-2 variants E1 and E8 containing a
P1 Leu. The graph shows pairwise comparisons of relative KD values of inhib-
itor binding to the indicated proteinases, normalized to the E1 value.
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seen with CELA3A suggesting that the P4 position might be a
selectivity determinant. Unexpectedly, however, when binding
of inhibitor variants with P4 His(E1) versus Ala(E12) to
CELA3A and CELA3B was tested, a similar 3.6- and 3.2-fold
reduction in affinity was observed, respectively; whereas bind-
ing to porcine CELA1 was decreased by 2-fold (Fig. 6), indicat-
ing that the P4position plays aminor role in determining bind-
ing affinity anddoes not confer selectivity among elastases. This
conclusion is consistent with the published view that porcine
CELA1 contains only three important subsites (S1–S3) inter-
acting with the primed side of the substrate (12).
With respect to chymotrypsins, the presence of a P4 Ala
(versus His) reduced affinity toward CTRC by 14-fold, while
binding to CTRB1 and CTRB2 remained unchanged. The
exceptionally strong binding of inhibitor variants with a P4His
to CTRC was somewhat surprising as we previously found that
an acidic P4 residue (Glu or Asp) was required for high affinity
(49). The significantly better performance ofHis overAla at this
position suggests that His is capable of forming stabilizing,
most probably H-bonding, or other polar interactions with the
S4 site.
P4 Position Is an Important Determinant of CELA1, CTRB1,
and CTRB2 Inhibition—The CELA1-selected sequence logo
showed dramatic conservation of anAla at position P4, whereas
the CELA3A- and CELA3B-selected logos indicated low con-
servationwith a slight preference for Tyr andAla.We evaluated
the effect of P4 Ala versus Tyr combined either with a P2 Leu
(E1 versus E10) or a P2 Tyr (E9 versus E11) in direct binding
experiments. Consistent with the logos, the presence of either
Ala or Tyr at the P4 position had small effects (range 1.1–2-
fold) on binding of the inhibitors to CELA3 isoforms. Surpris-
ingly, similarly small (2–3-fold) effects were observed with
CELA1 despite the strong selection for an Ala at the P4 posi-
tion. This suggests that the preference for a P4 Ala is context-
dependent and requires the presence of optimal residues at the
P1 and P2 positions.
A P4Ala (versusTyr) decreased inhibition of CTRCby 2-fold
(with P2 Leu) and 9-fold (with P2Tyr). Remarkably, however,
a P4 Ala (versus Tyr) improved binding to CTRB1 and CTRB2
by 74- and 205-fold (with a P2 Tyr) and 49- and 272-fold (with
a P2 Leu), respectively (Fig. 7).
FIGURE 5. Effect of the P2 residue on the inhibition of elastases and chy-
motrypsins by SGPI-2 variants. A, inhibition by variants E2 and E7 contain-
ing aP1 Ile andaP2 Leu versusGlu. Pairwise comparisonsof relativeKD values
of inhibitor binding to the indicated proteinases are shown, normalized to
the E2 value. ND, no inhibition was detected. B, inhibition by variants E1 and
E9 containing a P1 Leu and a P2 Leu versus Tyr. Pairwise comparisons of
relative KD values normalized to the E1 value are shown. C, inhibition by vari-
ants E10 and E11 containing a P1 Leu, a P4 Ala, and a P2 Leu versus Tyr.
Pairwise comparisons of relative KD values normalized to the E10 value are
shown.
FIGURE 6. Effect of the P4 residue (His versus Ala) on the inhibition of
elastases and chymotrypsins by SGPI-2 variants E1 and E12 containing a
P1 Leu. The graph shows pairwise comparisons of relative KD values of inhib-
itor binding to the indicated proteinases, normalized to the E1 value.
CELA3A and CELA3B Substrate Specificity
2696 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 292•NUMBER 7•FEBRUARY 17, 2017
 at U
N
IV
ERSITY
 O
F D
EBRECEN
 on M
arch 9, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
P1 Preference of Elastases on p-Nitroanilide Peptide Sub-
strates Is Skewed toward Ala—The widely accepted notion that
elastases favor a P1 Ala over other amino acid side chains has
been supported by a biased literature where most studies used
various synthetic ester and amide substrates with a P1 Ala (11,
13, 23, 32, 34, 36). To re-investigate this phenomenon in amore
systematicmanner, wemeasured kinetic parameters for human
CELA3A, CELA3B, and pig CELA1 on a series of small peptide
substrates with the general sequence of Suc-Ala-Ala-Pro-Xaa-
p-nitroanilide, where XaawasAla, Val, Leu, Ile,Met, Ser, or Gly
(Table 4). Considering catalytic efficiency (kcat/Km), we found
that CELA3B was on average 2.8-fold (range 1.6–4-fold) more
active on these substrates than CELA3A. Relative to the human
elastases, porcine CELA1 was superior on all substrates to a
varying extent (range 1.1–47-fold), with the largest differences
observed on the alanyl, leucyl, and seryl substrates. This higher
activity might be partially due to the overwhelming Ala prefer-
ence of the S4 site of CELA1. There was no quantitative corre-
lation between KD values measured for the inhibitor variants
with different P1 residues and catalytic efficiencies of the anal-
ogous p-nitroanilide substrates. Remarkably, when relative cat-
alytic efficiencies were compared, the substrate with P1Alawas
cleaved by all elastases 8–10-fold better compared with the
second best substrate with a P1 Val or Leu (Fig. 8). The results
confirm the apparent Ala specificity of elastases on small pep-
tide substrates, which stands in contrast with published cleav-
age patterns on larger protein substrates and our binding data
using phage display-selected SGPI-2 variants.
Discussion
In this study we used phage display-assisted directed evolu-
tion of a small protein proteinase inhibitor to characterize the
substrate specificity of human pancreatic elastases CELA3A
and CELA3B. These experiments were undertaken to clarify
whether the primate-specific duplication of the CELA3 gene
resulted in the evolution of unique proteinase specificities. This
question seemed particularly interesting in light of the previ-
ously reported observation that the human ortholog of the
archetypal pig pancreatic elastase CELA1 is not expressed in
the human pancreas (17, 18). It seemed reasonable to speculate
that gene duplication might have created a functional substi-
tute for the missing CELA1. To address this problem, we used
phage-displayed libraries of the SGPI-2 proteinase inhibitor to
select tight-binding variants against human CELA3A and
CELA3B as well as porcine CELA1. In this library, six amino
acid positions in the reactive binding loop of the inhibitor were
fully randomized (see Fig. 1). On the basis of the CELA3-se-
lected sequence patterns, we recombinantly expressed and
purified 12 SGPI-2 inhibitor variants and determined their
binding to CELA3A, CELA3B, and porcine CELA1. Further-
more, to characterize selectivity, affinity toward human chy-
motrypsins CTRC, CTRB1, and CTRB2 was measured. The
success of the selection process was confirmed by themarkedly
improved binding of inhibitor variants carrying the loose con-
sensus sequence compared with the parent SGPI-2 molecule.
Interestingly, affinity of the CELA3 consensus variants was
comparable and showed little isoform selectivity.
With respect to the primary substrate specificity of the elas-
tases studied, we made the following observations. (i) The P1
specificity of human CELA3A, CELA3B, and porcine CELA1
was broad and overall very similar, directed toward aliphatic
amino acid side chains Leu, Ile, Val, and Ala. (ii) A P1 Met was
preferred by porcine CELA1, but it was less favored by human
elastases. (iii) Inhibitors with a P1 Ser were poorly recognized
by all elastases tested. The observations confirm and extend
previous studies where cleavage specificity of pig CELA1, pig
proteinase E, and humanCELA3Bwas examined onmacromo-
lecular substrates. Thus, porcine CELA1 was shown to hydro-
lyze elastin at Ala-Ala and Ala-Gly peptide bonds and to cleave
oxidized insulin A and B chains after Ala, Val, Ser, andGly (6, 8,
9). A 1977 “meta-analysis” of all publishedCELA1 cleavage sites
in proteins found that P1 Ile, Val, and Ala were preferred, but
cleavages after Leu, Thr, and Ser were also reported (14). Por-
cine proteinase E cleaved oxidized ribonuclease and insulin
chains mostly after Ala, Val, Ser, and Thr residues; one Ile-Thr
peptide bond in ribonuclease was also extensively hydrolyzed
FIGURE 7. Effect of the P4 residue on the inhibition of elastases and chy-
motrypsins by SGPI-2 variants.A, inhibition by variants E1 and E10 contain-
ing a P1 Leu, a P2 Leu, and a P4 Tyr versus Ala. Pairwise comparisons of
relative KD values of inhibitor binding to the indicatedproteinases are shown,
normalized to the E1 value. B, inhibition by variants E9 and E11 containing a
P1 Leu, a P2 Tyr, and a P4 Tyr versus Ala. Pairwise comparisons of relative KD
values normalized to the E9 value are shown.
CELA3A and CELA3B Substrate Specificity
FEBRUARY 17, 2017•VOLUME 292•NUMBER 7 JOURNAL OF BIOLOGICAL CHEMISTRY 2697
 at U
N
IV
ERSITY
 O
F D
EBRECEN
 on M
arch 9, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
(30, 42). Finally, human CELA3B digested oxidized insulin
chains and glucagonpreferably afterAla, Val, andLeu, although
cleavages after Ser, Thr, and His were also observed (43). Inter-
estingly, in protein substrates elastases often cleaved after a P1
Ser and Thr, but our substrate-like inhibitor with a P1 Ser
exhibited poor binding. Although the reason for this discrep-
ancy is not readily apparent, cleavage after the relatively polar
Ser may be more context-dependent and may require different
subsite interactions than those selected here with more hydro-
phobic P1 side chains. Alternatively, the more rigid binding
loop in the inhibitor may pose unique constraints that prevent
accommodation of a P1 Ser in the elastase primary binding
pocket.
While the published literature on elastase cleavage sites in
protein substrates seems to agree with our results, quantitative
data on cleavage rates are scarce, and a direct comparison is
difficult. KD values for substrate-like protein inhibitors tend to
correlate with kcat/Km values for hydrolysis of the analogous
protein substrates, but thismay not be generally applicable (52).
Additional studies are required to see how closely the substrate
specificity profiles determined with substrate-like inhibitors
actually mimic the cleavage preferences of elastases on protein
substrates.
The commonly cited Ala specificity of elastases is partly
explained by a biased literature that preferentially used small
amide and ester substrates with a P1 Ala to study elastase activ-
ity. Curiously, amide substrates with a P1 Ala are markedly
better hydrolyzed by elastases than those with any other P1
residue (11, 13, 32). We confirmed this phenomenon by mea-
suring kinetic parameters on Suc-Ala-Ala-Pro-Xaa-p-nitroani-
lide peptides, where Xaa was Ala, Val, Ile, Leu, Met, Ser, or Gly.
All elastases studied cleaved the P1 Ala substrate with 8–10-
fold better catalytic efficiency than the next best substrate.
Although an explanation for the superiority of a P1 Ala in the
context of small amide substrates is not obvious, our binding
data with substrate-like proteinase inhibitors and published
cleavage site preferences in proteins do not support the conten-
tion that a P1 Ala would be favored over other small side chains
by elastases. Interestingly, when a series of tripeptide thioben-
zyl ester substrates (Boc-Ala-Ala-Xaa-thiobenzyl ester) was
tested, the order of cleavage preference by pig CELA1 was
Leu  Met  Ala Val  Ile  Ser with only about 2-fold
differences between substrates (15).
Our results also offered insight into the extended subsite
specificities for human CELA3A, CELA3B, and pig CELA1. In
this regard, prior studies on pig CELA1 found that it contained
eight subsites extending from P5 through P3 (12). The S1 site
preferredLys (versusAla, Tyr, orGlu); the S2 site preferredPhe
(versusAla), and the S3 site preferred aromatic side chains (10,
12, 53). Another study found that P1 Ala, Leu, Met, Val, and
even Arg were well tolerated, whereas a P1 Gly was not pre-
ferred (54). Based on the cleavage pattern of oxidized insulin
chains by porcine proteinase E, the authors speculated on sub-
site preference and suggested that at P2 Gln or Ile are not
favored but Glu and Leu are allowed and at P1 Gln and at P2
Lys also have negative effects (42). In our phage display and
inhibitor binding experiments, we did not find a marked
difference in the extended subsite preference of human
CELA3A and CELA3B; both isoforms preferred a P1 Met,
whereas interactions with positions P4, P2, and P4 were
less selective. In contrast, the porcine CELA1-selected logo
indicated significant subsite preference at position P4 (Ala)
and P2 (Tyr/Trp). The importance of a P2 Tyr was verified
in direct binding experiments, whereas that of a P4 Ala
appeared to be context-dependent.
TABLE 4
Enzyme kinetic parameters of human CELA3A, CELA3B, and porcine CELA1 on Suc-Ala-Ala-Pro-Xaa-p-nitroanilide substrates, where Xaa stands
for the amino acids indicated in the table heading.
Measurements were performed at 22 °C as described under “Experimental Procedures.” Although not shown, substrates containing Lys, Arg, Trp, Tyr, Phe, Asn, or Gln at
the Xaa position were not cleaved by the elastases. The units of measure were as follows: kcat (s1),Km (M), and kcat/Km (M1 s1). Average values S.E. (n 3) are shown.
ND means no cleavage was detected.
Ala Val Leu Ile Met Ser Gly
CELA3A
kcat 22.9 0.7 2.44 0.08 1.16 0.03 0.99 0.01 0.24 0.01 0.14 0.01 ND
Km 1089 70 1178 82 722 53 1060 27 452 52 1447 156 ND
kcat/Km 2.1 104 2.1 103 1.6 103 9.3 102 5.3 102 9.9 101 ND
CELA3B
kcat 24.8 0.5 3.66 0.10 1.01 0.01 1.25 0.02 0.24 0.01 0.26 0.01 ND
Km 374 22 430 32 259 8 484 23 288 19 984 51 ND
kcat/Km 6.6 104 8.5 103 3.9 103 2.6 103 8.3 102 2.6 102 ND
CELA1
kcat 115 1 16.9 0.7 57.8 1.3 2.87 0.06 0.70 0.01 5.62 0.16 1.86 0.05
Km 166 4 1029 93 785 30 995 43 540 30 2311 108 1555 74
kcat/Km 6.9 105 1.7 104 7.4 104 2.9 103 1.3 103 2.4 103 1.2 103
FIGURE 8. Catalytic efficiency of human elastases CELA3A and CELA3B
and porcine CELA1 on small peptide substrates. Enzyme kinetic parame-
ters were determined on Suc-Ala-Ala-Pro-Xaa-p-nitroanilide substrates,
where Xaa stands for the indicated P1 amino acid residues, as described
under “Experimental Procedures” and Table 4. Specificity constants (kcat/Km)
were expressed as percent of the value obtained with the Ala substrate.
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Selectivity of the newly evolved SGPI-2 variants was tested
against three human chymotrypsins, CTRB1, CTRB2, and
CTRC. In general, variants inhibited CTRB1 and CTRB2 poor-
ly; measurable inhibition was only observed with a P1 Leu. A
strong selectivity determinant against these two chymotrypsins
was identified at the P4 position where the presence of a Tyr
(versus Ala) markedly reduced affinity. Remarkably, inhibitor
variants with a P1 Leu turned out to be superior CTRC inhibi-
tors with picomolar affinity. Indeed, the reactive loop sequences
of the strongly binding inhibitors ((Tyr/Ala)-Cys-Thr-Leu-Met-
(Leu/Tyr)-Cys-His) were very similar to the best CTRC inhibitor
variant selected in our preceding study (Ala-Cys-Thr-Leu-Met-
Leu-Cys-Glu) (49). Although previously we assigned significance
to the presence of the acidic residue at the P4 position in deter-
mining high affinity binding, the current data indicate that a His
residue is alsocompatible at this site and is significantlybetter than
an Ala. As we observed before, CTRC is relatively tolerant to
changes at the P2position; however, we foundnow that a P1Arg
inhibited binding toCTRCby 20-fold, although it had only a small
effect on other human chymotrypsins. In fact, the absence of a P1
Arg in our earlier phage display study already predicted that this
residue would be inhibitory for CTRC binding (49). As discussed
above, the somewhat unexpected efficacy of our selected inhibitor
variants against CTRC indicates that within the human chymot-
rypsin-like enzymes the SGPI-2 scaffold is uniquely compatible
with this proteinase.
In summary, we compared the substrate specificity of human
CELA3A, CELA3B, and porcine CELA1 elastases using phage
display selection of an SGPI-2 proteinase inhibitor library,
direct binding experiments with purified SGPI-2 variants, and
cleavage experiments with p-nitroanilide substrates. The
results demonstrate that the substrate specificity of CELA3A,
CELA3B, and CELA1 are similar with a P1 specificity broadly
directed toward aliphatic amino acid side chains. In accordance
with their more distant evolutionary relationship, we detected
specificity differences between theCELA3 andCELA1 paralogs
at the P4 and P2 positions. However, the extended subsite
specificities of the two CELA3 isoforms were comparable.
Thus, gene duplication of the CELA3 isoforms did not give rise
to a CELA1 surrogate, but it may have compensated for the loss
of CELA1 in the human pancreas by increasing the digestive
enzyme pool.
Experimental Procedures
Purification of Digestive Serine Proteinases—Human
CELA3A, CELA3B, CTRC, CTRB1, and CTRB2 proenzymes
carrying C-terminal His tags were expressed in HEK 293T cells
and purified from the conditioned medium by nickel-affinity
chromatography as described previously (44). The proenzymes
were activated with immobilized trypsin (catalog no. 20230,
ThermoFisher Scientific,Waltham,MA), and the trypsin beads
were removed by centrifugation. Porcine CELA1 (catalog no.
E0127) used for phage selectionwas purchased fromSigma, and
the enzyme used for kinetic and inhibition assays (code ESFF,
catalog no. LS006363) was fromWorthington.
Construction of the SGPI-2 Library—A protein-phage library
displaying SGPI-2 on the surface of M13 bacteriophage was
created as described previously (48–50). Briefly, the coding
sequence of SGPI-2 was fused to the p8 coat protein of M13,
and six positions in the binding loop of the inhibitor (Fig. 1)
were fully randomized in two consecutive Kunkel mutagenesis
steps. First, stop codons were introduced to eliminate any wild-
type background from the selection. Next, stop codons were
replaced by NNK codons (where NA, C, T, G and KG, T),
which encode all 20 amino acids. The resulting phagemid
library was electroporated into E. coli SS320. Cells were
infected with M13KO7 helper phage (New England Biolabs,
Ipswich, MA) and grown overnight to produce the protein-
phage library.
Selection of the SGPI-2 Library on Human CELA3A and
CELA3B—As simpler surface immobilization methods proved
to be inefficient with these isoforms, solution phase selection
was performed followed by aHis tag/immobilizedmetal affinity
chromatography capture. In the first round of selection, 1012
phage particles displaying SGPI-2 variants were incubated in
the absence or presence of 50 nM His-tagged CELA3A or
CELA3B in 50 mM Tris-HCl (pH 8.0), 300 mM NaCl, 0.1%
Tween 20, and 20 mM imidazole (wash buffer) for 1 h. Phage
particles incubated inwash buffer containing no elastase served
as control for enrichment determination. Aliquots of Dyna-
beads His Tag Isolation and Pulldown (Thermo Fisher Scien-
tific) (5 l) were blocked with 500 l of 50 mM Tris-HCl (pH
8.0), 300 mM NaCl, 0.1% Tween 20, 5 mg/ml BSA, and 50 mM
imidazole (block buffer) to prevent nonspecific binding of the
phage particles to the beads and washed with 500 l of wash
buffer. Elastase-bound phages were then captured through the
His tag by incubating with the pre-blocked Dynabeads for 5
min. To separate bound phages, the beads were collected using
a magnet, and unbound phages were removed by rinsing the
beads twice with 1.5 ml of wash buffer. Bound phages were
eluted with 1.4 ml of 250 mM imidazole in 50 mM Tris-HCl (pH
8.0), 300 mM NaCl, and 0.1% Tween 20 (elution buffer). Then,
4.5 ml of midlog-phase E. coli XL1 Blue cells were infected by
0.5 ml of phages. After 30min of incubation at 37 °C with shak-
ing, 20 l of cells were removed, and 10-fold serial dilutions
were prepared. Cell dilutions (10l) were transferred onto pre-
dried LB/Amp plates and incubated at 37 °C overnight. The
number of infected cells generated by elastase-selected versus
control phages defined the enrichment of target-binding phage
clones over nonspecific binders. The rest of the 5ml of infected
E. coli cultures were superinfected with M13KO7 helper phage
and grown overnight to propagate the phages. The second and
third rounds of selectionwere carried out similarly as described
above with the exception that the propagated and isolated
phages were pre-cleared on blocked Dynabeads to eliminate
background-binding clones.
Phage ELISA of Human CELA3A and CELA3B Selected
SGPI-2 Clones—Individual clones from the third round of
selection were tested for target binding in phage ELISA. Clones
were grown in single loose tubes (National Scientific), and the
supernatant containing the inhibitor-displaying phages was
used in the assays. Aliquots (1 l) of Dynabeads were trans-
ferred to 96-well microtiter plates and blocked with 100 l of
block buffer for 30 min. After removal of the block buffer, the
beads were washed with 100 l of wash buffer. On a separate
microtiter plate, 50 l of phage supernatant was incubated in
CELA3A and CELA3B Substrate Specificity
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the absence (control) or presence of 7 nM CELA3A or CELA3B
(final concentration) in a 200-l final volume for 1 h. The elas-
tase-phage incubates were transferred to the blocked beads and
incubated for 5min. Non-bound phages were removed, and the
beads were washed four times with 200l of wash buffer. Then,
50 l of HRP-conjugated anti-M13 antibody (GE Healthcare)
diluted 5000-fold in wash buffer was added to each well for 30
min. The unbound antibody was discarded, and the beads were
first washed with 200 l of wash buffer and then with 200 l of
50 mM Tris-HCl (pH 8.0) and 300mMNaCl. For color develop-
ment, 50 l of 3,3,5,5-tetramethylbenzidine substrate was
added to the wells, and the reaction was stopped with 50 l of
1 M HCl. The absorbance at 450 nm was measured after the
removal of the beads from the solutions.
Selection of the SGPI-2 Library on Porcine CELA1—Three
selection cycles were performed as described previously (48–
51). Briefly, 5 g/well porcine CELA1 in phosphate-buffered
saline (pH 7.2) (PBS) was immobilized in 12 wells of Nunc
Immobilizer Amino Plates for 3 h.Wells without CELA1 served
as control. The wells were blocked with 200 l of 5 mg/ml BSA
in PBS for 1 h. Then, 100l of phages in PBS, 5mg/ml BSA, and
0.05% Tween 20 was added to the blocked wells and incubated
for 2.5 h. After rinsing the wells with PBS, bound clones were
eluted with 100 l of 0.1 M HCl, and the eluate was brought to
neutral pH by adding 1 M Tris base solution. Mid-log XL1-Blue
cells were infected with the eluted phages, titrated for determi-
nation of the enrichment ratio, superinfected with M13 KO7
helper phage, and grown overnight for target-binding phage
amplification.
Phage ELISA of Porcine CELA1-selected SGPI-2 Clones—
Individual clones from the third selection cycle were tested for
binding to CELA1 in phage ELISAs as described previously
(48–51). Porcine CELA1 (1.25 g/well in PBS) was immobi-
lized in Nunc Immobilizer Amino Plates.
DNA Sequence Analysis of Selected Phages—Clones with a
signal-to-noise ratio higher than 2were considered positive and
were Sanger sequenced (Table 1). In each of the randomized
positions, the frequency of the amino acids was normalized to
the expected frequency of their corresponding codons in the
NNK set. A dataset of 1000 sequences was generated based on
these normalized frequencies that served as input for sequence
logo generation by the WebLogo program (55).
Expression and Purification of SGPI-2 Variants—Based on
the sequence pattern of the inhibitor binding loops selected
against the human elastases, 12 different inhibitor variantswere
designed and created using PCR-based mutagenesis (Table 2).
The recombinant SGPI-2 variantswere expressed into the cyto-
plasm of E. coli SHuffle T7 cells (C3026, New England Biolabs)
fused to the C terminus of the E. coli protein-disulfide isomer-
ase DsbC following the strategy of Nozach et al. (56). The con-
struct also incorporated an N-terminal His tag and a TEV pro-
teinase cleavage site between the inhibitor and DsbC. The
fusion protein was purified by nickel-affinity chromatography
and processed byHis-tagged TEV proteinase. His-taggedDsbC
and TEV proteinase as well as any unprocessed SGPI-2 were
removed in a second nickel-affinity chromatography step.
Finally, inhibitor variants were purified to homogeneity on a
Phenomenex Jupiter 10u C4 300A column using reverse phase-
HPLC. The correct molecular weight of the proteins was veri-
fied by ESI-MS as described previously (49).
Determination of Concentrations—Active site titrated bovine
trypsin was used to determine the concentration of the pan-
specific serine proteinase inhibitor ecotin, which was then
used to measure the concentrations of the CTRC, CTRB1,
CTRB2, and pig CELA1 preparations. Because ecotin binds
CELA3A and CELA3B with lower affinity, eglin C was used to
measure active concentrations of human elastases. Eglin C was
purified as reported previously, and its concentration was
determined by titration against human CTRC (22). SGPI-2
variants E1, E2, E4, E8, E9, E10, and E12 were titrated against
CTRC and E11 against porcine CELA1. All titrations were per-
formed at enzyme concentrations at least 2 orders ofmagnitude
higher than the equilibrium dissociation constant of the inter-
action. Concentration of SGPI-2 variants E3, E5, E6, and E7was
measured by a protein assay (Micro BCA Protein Assay Kit,
Thermo Fisher Scientific) using E8 as standard.
Equilibrium Binding Assays—The KD values of the binding
reaction between SGPI-2 variants and pancreatic proteinases
were determined according to Empie and Laskowski (35) as we
described previously (48–50). Incremental amounts of the
inhibitor were incubated with a fixed enzyme concentration at
22 °C for 1 h in 0.1 M Tris-HCl (pH 8.0), 1 mMCaCl2, and 0.05%
Tween 20. The amount of free enzyme was then measured
using elastase substrates Suc-Ala-Ala-Pro-Ala-p-nitroanilide
or Suc-Ala-Pro-Ala-amido-methylcoumarin or chymotrypsin
substrates Suc-Ala-Ala-Pro-Phe-p-nitroanilide or Suc-Ala-
Ala-Pro-Phe-amido-methylcoumarin. The experimental data
were fitted with the following equation: y E (E	 x	 K

((E	 x	 K)∧2 4Ex))/2, where the independent variable x
represents the total inhibitor concentration; the dependent
variable y is the free proteinase concentration in equilibrium;K
isKD, and E designates the total proteinase concentration. Each
KD value was determined in two independent assays, and the
average values are presented.
Enzyme Kinetic Analysis—The activity of human CELA3A,
CELA3B, and porcine CELA1 was determined on a series of
chromogenic peptide substrates with the general structure of
Suc-Ala-Ala-Pro-Xaa-p-nitroanilide, where Xaa stands for Ala,
Arg, Asn, Gln, Gly, Ile, Leu, Met, Lys, Phe, Ser, Trp, Tyr, or Val.
Measurements were performed at 22 °C in 0.1 M Tris-HCl (pH
8.0), 1 mM CaCl2, and 0.05% Tween 20. Rates of substrate hy-
drolysis were plotted as a function of the substrate concentra-
tion, and Km and kcat values were determined from hyperbolic
fits to the data points.
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